Aptevo Therapeutics (NASDAQ:APVO) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note issued on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm reduced their price objective on Aptevo Therapeutics from $20,535.00 to $10,952.00 and set a “buy” rating for the company in a research report on Monday, September 23rd.

Aptevo Therapeutics Stock Performance

Shares of APVO stock opened at $9.70 on Monday. The business has a 50 day moving average of $306.86 and a two-hundred day moving average of $502.97. Aptevo Therapeutics has a 52 week low of $5.11 and a 52 week high of $399.60.

Institutional Trading of Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.